Insider Transactions in Q3 2024 at Kiniksa Pharmaceuticals, Ltd. (KNSA)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,500
-13.01%
|
$420,000
$24.99 P/Share
|
|
Sep 23
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.92%
|
$10,000
$1.59 P/Share
|
|
Sep 03
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
60,692
-27.64%
|
$1,577,992
$26.61 P/Share
|
|
Sep 03
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
60,692
+17.67%
|
$121,384
$2.83 P/Share
|
|
Sep 03
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
68,506
-39.85%
|
$1,781,156
$26.61 P/Share
|
|
Sep 03
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
68,506
+26.97%
|
$685,060
$10.63 P/Share
|
|
Sep 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
329
-1.23%
|
$8,554
$26.74 P/Share
|
|
Sep 02
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
775
+2.81%
|
-
|
|
Sep 02
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
835
-1.58%
|
$21,710
$26.74 P/Share
|
|
Sep 02
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,725
+3.16%
|
-
|
|
Sep 02
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
577
-0.46%
|
$15,002
$26.74 P/Share
|
|
Sep 02
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+1.55%
|
-
|
|
Sep 02
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,177
-3.84%
|
$82,602
$26.74 P/Share
|
|
Sep 02
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,569
+7.36%
|
-
|
|
Sep 02
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
956
-4.0%
|
$24,856
$26.74 P/Share
|
|
Sep 02
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,861
+7.22%
|
-
|
|
Sep 02
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
345
-1.56%
|
$8,970
$26.74 P/Share
|
|
Sep 02
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
994
+4.31%
|
-
|
|
Sep 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,755
-9.58%
|
$71,630
$26.74 P/Share
|
|
Sep 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,490
+18.42%
|
-
|
|
Sep 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,994
-3.75%
|
$51,844
$26.74 P/Share
|
|
Sep 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,121
+7.2%
|
-
|
|
Sep 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,322
-1.06%
|
$34,372
$26.74 P/Share
|
|
Sep 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,499
+3.49%
|
-
|
|
Sep 01
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,967
-9.47%
|
$207,142
$26.74 P/Share
|
|
Sep 01
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,474
+16.38%
|
-
|
|
Sep 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,260
-9.3%
|
$58,760
$26.74 P/Share
|
|
Sep 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,444
+15.45%
|
-
|
|
Sep 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,393
-6.2%
|
$36,218
$26.74 P/Share
|
|
Sep 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,089
+15.39%
|
-
|
|
Aug 27
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
17,500
-12.74%
|
$455,000
$26.91 P/Share
|
|
Aug 27
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.78%
|
$10,000
$1.59 P/Share
|
|
Jul 23
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
22,000
-8.86%
|
$572,000
$26.59 P/Share
|
|
Jul 23
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+23.96%
|
$22,000
$1.86 P/Share
|
|
Jul 23
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
24,248
-55.74%
|
$581,952
$24.79 P/Share
|
|
Jul 23
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
24,248
+35.79%
|
$266,728
$11.1 P/Share
|
|
Jul 23
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Direct |
136,124
-30.0%
|
$3,403,100
$25.1 P/Share
|
|
Jul 23
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
136,124
+40.6%
|
$136,124
$1.59 P/Share
|
|
Jul 15
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
480
+2.11%
|
$7,200
$15.65 P/Share
|
|
Jul 15
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
211
+1.13%
|
$3,165
$15.65 P/Share
|